Skip Navigation

Cardiovascular Research 1993 27(5):861-867; doi:10.1093/cvr/27.5.861
© 1993 by European Society of Cardiology
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Abrahamsson, C
Right arrow Articles by Carlsson, L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abrahamsson, C
Right arrow Articles by Carlsson, L
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1993, European Society of Cardiology

Electrophysiological and inotropic effects of H 234/09 (almokalant) in vitro: a comparison with two other novel IK blocking drugs, UK-68,798 (dofetilide) and E-4031

C Abrahamsson, G Duker, C Lundberg and L Carlsson

Cardiovascular Pharmacology, Preclinical Research and Development, Astra Hässle, S-431 83 Mölndal, Sweden: C Abrahamsson, G Duker, C Lundberg, L Carlsson.

Correspondence to Christina Abrahamsson.

Objective: The aim was to compare the electrophysiological and inotropic effects of the novel class III agents H 234/09, UK-68,798, and E-4031 in vitro. Methods: The electrophysiological effects were investigated by recording transmembrane action potentials in the isolated ventricular muscle and Purkinje fibres of the rabbit; effects on force (adjusted to the maximum isoprenaline response) and refractoriness were investigated in the isolated cat papillary muscle. Results: It was shown that all the drugs induced a concentration dependent prolongation of the action potential duration, which was much more pronounced in the Purkinje fibres than in the ventricular muscle. However, when compared at concentrations giving a 15% increase of the action potential duration in ventricular muscle, H 234/09 was significantly less effective in the Purkinje fibres than the other two drugs. In the cat papillary muscle all drugs induced an increase in force development. This increase tended to parallel the increase in effective refractory period. However, at prolongations of effective refractory period of more than approximately 50% the increase in developed force levelled off. Conclusions: All the class III agents investigated showed a positive inotropic effect, which may be of advantage when compared to conventional class I antiarrhythmic agents, which have cardiodepressent actions. Compared to UK-68,798 and E-4031, H 234/09 showed a less unfavourable profile in terms of dispersion of repolarisation, which theoretically may reduce the risk of arrhythmias associated with delayed repolarisation. However, this less unfavourable profile must, like the positive inotropic effect, ultimately be investigated in clinical trials.

Cardiovascular Research 1993;27:861-867

KEYWORDS isolated myocardium; ventricular muscle; Purkinje fibre; action potential; inotropy; dispersion of repolarisation; class III antiarrhythmic agents


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
P. M.R. Orth, J. C. Hesketh, C. K.H. Mak, Y. Yang, S. Lin, G. N. Beatch, A. M. Ezrin, and D. Fedida
RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents
Cardiovasc Res, June 1, 2006; 70(3): 486 - 496.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
J.P. Vilaine, C. Thollon, N. Villenueve, and J.L. Peglion
Procoralan, a new selective If current inhibitor
Eur. Heart J. Suppl., September 1, 2003; 5(suppl_G): G26 - G35.
[Abstract] [PDF]

Home page
 J Am Coll CardiolHome page
M. R. Lauer
Dofetilide: is the treatment worse than the disease?
J. Am. Coll. Cardiol., March 15, 2001; 37(4): 1106 - 1110.
[Full Text] [PDF]

Home page
 Cardiovasc ResHome page
G. J Amos, C. Abrahamsson, G. Duker, L. Hondeghem, M. Palmer, and L. Carlsson
Potassium and calcium current blocking properties of the novel antiarrhythmic agent H 345/52: implications for proarrhythmic potential
Cardiovasc Res, February 1, 2001; 49(2): 351 - 360.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. P. Mounsey and J. P. DiMarco
Dofetilide
Circulation, November 21, 2000; 102(21): 2665 - 2670.
[Full Text] [PDF]

Home page
 Cardiovasc ResHome page
L. Eckardt, W. Haverkamp, M. Borggrefe, and G. Breithardt
Experimental models of torsade de pointes
Cardiovasc Res, July 1, 1998; 39(1): 178 - 193.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. Toyama, K. Kamiya, J. Cheng, J.-K. Lee, R. Suzuki, and I. Kodama
Vesnarinone Prolongs Action Potential Duration Without Reverse Frequency Dependence in Rabbit Ventricular Muscle by Blocking the Delayed Rectifier K+ Current
Circulation, November 18, 1997; 96(10): 3696 - 3703.
[Abstract] [Full Text]

Home page
 Circ. Res.Home page
H. J. Duff, Z.-P. Feng, and R. S. Sheldon
High- and Low-Affinity Sites for [3H]Dofetilide Binding to Guinea Pig Myocytes
Circ. Res., October 1, 1995; 77(4): 718 - 725.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.